You are here

Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

Last updated on November 21, 2019

FOR MORE INFORMATION
Study Location
Healthcare Corporation MEDOC Medical Dock&Clinic
Nagoya, Aichi, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Hypertension, Hypercholesterolemia, Angina Pectoris
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Subject with both hypertension and hypercholesterolemia must meet the following (1),
and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

- Subject with both angina pectoris and hypercholesterolemia must meet the following
(1), and the following (2) or (3):

- (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2,
and who meet the following criteria; Subjects with well controlled BP value (BP value

- (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2

- (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3
months during the previous 12 months, with LDL-C ≥ 160 mg/dL, LDL-C TG

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects who need three or more multi-antihypertensive therapies to achieve the target
BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is
defined as systolic blood pressure

- Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ?
160 mg/dL even though Atorvastatine 10 mg has administrated

NCT01190007
Pfizer
Completed
Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Pulmonary Arterial Hypertension
NCT02060487
All Genders
18+
Years
Multiple Sites
Pulmonary Arterial Hypertension
NCT03364244
All Genders
0+
Years
Tokyo,
Descriptive Information
Brief Title  ICMJE Open Label Study To Evaluate The Long-Term Safety Profiles Of Caduet In Japanese Patients
Official Title  ICMJE A Multi-Center, Open Label Study To Evaluate Long Term Safety Of Caduet In Patient With Both Of Hypertension And Hypercholesterolemia, Or With Both Of Angina Pectoris And Hypercholesterolemia
Brief SummaryThe primary objective is to investigate the safety of Caduet (2.5 mg/5 mg, 2.5 mg/10 mg, 5 mg/5 mg or 5 mg/10 mg as dose of Amlodipine/Atorvastatin) during 52 weeks treatment period in Japanese patients with both of hypertension and hypercholesterolemia, or with both angina pectoris and hypercholesterolemia.
Detailed DescriptionNot Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 4
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE
  • Hypertension
  • Hypercholesterolemia
  • Angina Pectoris
Intervention  ICMJE Drug: Caduet
One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
Study Arms  ICMJE Experimental: Caduet
Intervention: Drug: Caduet
Publications *Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Actual Enrollment  ICMJE
 (submitted: February 22, 2012)
159
Original Estimated Enrollment  ICMJE
 (submitted: August 25, 2010)
150
Actual Study Completion Date  ICMJE February 2012
Actual Primary Completion DateFebruary 2012   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Subject with both hypertension and hypercholesterolemia must meet the following (1), and the following (2) or (3):
  • (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0)
  • (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
  • (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ? 160 mg/dL, LDL-C < 250 mg/dL, and TG < 400 mg/dL at Week -2
  • Subject with both angina pectoris and hypercholesterolemia must meet the following (1), and the following (2) or (3):
  • (1) Subjects who take Amlodipine 2.5mg/day or 5mg/day at least 28 days before Week -2, and who meet the following criteria; Subjects with well controlled BP value (BP value < 140/90mmHg at Week 0), and subjects with clinically stable of angina pectoris
  • (2) Subjects who take Atorvastatine 5mg/day or 10mg/day at least 28days before Week -2
  • (3) Statin-naïve patient, defined as receiving no statin therapy for more than 3 months during the previous 12 months, with LDL-C ? 160 mg/dL, LDL-C < 250 mg/dL, and TG < 400 mg/dL at Week -2

Exclusion Criteria:

  • Subjects who need three or more multi-antihypertensive therapies to achieve the target BP level or uncontrolled status of hypertension at Week 0 (V1); the target BP level is defined as systolic blood pressure < 140mmHg and diastolic blood pressure < 90 mmHg.
  • Uncontrolled or uncontrollable status of hypercholesterolemia at Week -2; A LDL-C ? 160 mg/dL even though Atorvastatine 10 mg has administrated
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 20 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Japan
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT01190007
Other Study ID Numbers  ICMJE A3841064
Has Data Monitoring CommitteeNo
U.S. FDA-regulated ProductNot Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible PartyPfizer
Study Sponsor  ICMJE Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Pfizer CT.gov Call CenterPfizer
PRS AccountPfizer
Verification DateDecember 2012

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now